Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, ANI Pharmaceuticals (ANIP) reported revenue of $266.04 million, up 25.9% over the same period last year. EPS came in at $2.21, compared to $1.80 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $262.73 million, representing a surprise of +1.26%. The company delivered an EPS surprise of +9.95%, with the consensus EPS estimate being $2.01.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenues- Generic pharmaceutical products: $99.05 million compared to the $96.93 million average estimate based on three analysts. The reported number represents a change of +9.7% year over year.
• Total Net Revenues- Rare Disease: $135.84 million versus $141.01 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +30.7% change.
• Net Revenues- Rare Disease and Brands- ILUVIEN and YUTIQ: $18.72 million versus the three-analyst average estimate of $20.69 million. The reported number represents a year-over-year change of -16.1%.
• Net Revenues- Rare Disease and Brands- Cortrophin Gel: $117.13 million versus the three-analyst average estimate of $120.35 million. The reported number represents a year-over-year change of +43.5%.

View all Key Company Metrics for ANI here>>>

Shares of ANI have returned -1.4% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research